Shares of Cipla were up 3% at Rs 622 per share on the BSE in early morning trade after the company said that it has received approval from the US Food and Drug Administration (USFDA) to market Efavirenz tablets, used to treat HIV-1 infections in adults.
The stock of pharmaceutical company is 6.6% away from its 52-week high of Rs 663 touched on November 7, 2017 on the BSE.
“The company has received final approval for its Abbreviated New Drug Application (ANDA) for Efavirenz tablets 600mg from the United States Food and Drug Administration (USFDA),” Cipla said in a
The stock of pharmaceutical company is 6.6% away from its 52-week high of Rs 663 touched on November 7, 2017 on the BSE.
“The company has received final approval for its Abbreviated New Drug Application (ANDA) for Efavirenz tablets 600mg from the United States Food and Drug Administration (USFDA),” Cipla said in a